BACIT Limited
March 2016 Factsheet KEY DETAILS INVESTMENT METHODOLOGYNet Assets Inception Date
NAV Total Return Since Inception NAV Per Share (£)
Share Price (Mid Market) (£) Ex-Div (16 July 2015)
£470.4m
26 October 2012
29.54%
£1.2229
£1.3150
2.1p
BACIT Limited ("BACIT") targets attractive medium to long term returns by investing in leading long only and alternative investment funds with proven managers and across multiple asset classes. The composition of the investment portfolio will vary over time in terms of asset classes, strategies, managers and funds; BACIT intends to be invested in at least 15 distinct investment funds or managed account strategies over time. Further, BACIT invests in the CRT Pioneer Fund LP (the "Pioneer Fund") and may also invest in other drug development and medical innovation projects undertaken by The Institute of Cancer Research, subject to limitations on the amount of its NAV that it may invest in such projects in any year.
Annual Donation (% of NAV) 1% Financial Year End 31 March
BACIT invests only where the relevant investment manager provides investment capacity on a "gross return" basis, meaning that BACIT and its subsidiaries (the "Group") do not bear the impact of management or
SEDOL ISIN
Bloomberg Ticker
B8P59C0 GG00B8P59C08
BACT:LN
performance fees on its investments. This does not apply to the investment in the Pioneer Fund. Investing on
a "gross return" basis is achieved by the relevant manager or fund agreeing not to charge management or performance fees, by rebating or donating to the Group any management or performance fees charged or otherwise arranging for the Group to be compensated so as effectively to increase its investment by the amount of any such fees. BACIT donates 1% of its NAV each year to charity (50% to The Institute of Cancer Research and 50% to The BACIT Foundation).
NAV TOTAL RETURN VERSUS INDICESas at 31 March 1M 3M YTD BACIT Limited
1.45
1.40
1.35
1.30
Share Price
NAV Total Return
2.73% 3.14% 3.14%
0.08% -2.52% -2.52%
1.25
1.20
1.15
1.10
MSCI World (TR, $)
6.79% -0.35% -0.35%
1.05
Mar 16
Feb 16
Jan 16
Dec 15
Nov 15
Oct 15
Sep 15
Aug 15
Jul 15
Jun 15
May 15
Apr 15
Mar 15
Feb 15
Jan 15
Dec 14
Nov 14
Oct 14
Sep 14
Aug 14
Jul 14
Jun 14
May 14
Apr 14
Mar 14
Feb 14
Jan 14
Dec 13
Nov 13
Oct 13
Sep 13
Aug 13
Jul 13
Jun 13
May 13
Apr 13
Mar 13
Feb 13
Jan 13
Dec 12
Nov 12
Oct 12
1.00
HFRIFOFS Index | 2.16% | -3.43% | -3.43% | ||||||||||||
FT All-Share (TR, £) | 1.94% | -0.41% | -0.41% | BACIT Limited | HFRI Fund of Funds Strategic Index | FT All-Share (TR, £) MSCI World (TR, $) | |||||||||
PERFORMANCE (% TOTAL RETURN)* | |||||||||||||||
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | YTD | |||
2016 | -2.19 | -0.41 | 0.08 | - | - | - | - | - | - | - | - | - | -2.52 | ||
2015 | 2.73 | 1.01 | 3.58 | -0.16 | 1.53 | -2.56 | 2.15 | -2.07 | -2.13 | 1.60 | 2.39 | 1.44 | 9.69 | ||
2014 | -0.55 | 0.58 | 0.13 | -1.64 | 2.18 | -0.20 | -0.51 | 0.26 | 0.58 | 0.17 | 2.36 | 0.55 | 3.91 | ||
2013 | 4.12 | 2.55 | 2.58 | -0.16 | 2.69 | -1.57 | 1.24 | -1.23 | -0.78 | 2.94 | -0.42 | 0.82 | 13.32 | ||
2012 | - | - | - | - | - | - | - | - | - | - | 0.53 | 2.34 | 2.89 |
* Returns are inclusive of dividend distributions
COMPANY INFORMATION TOP 10 HOLDINGSStructure Closed End Investment Company | Fund | Investment Manager | Strategy | Asset | % of |
Domicile Guernsey | Class | NAV | |||
Listing London Stock Exchange | 1 Polar Capital Japan Alpha | Polar Capital | Long Bias | Equities | 6.4% |
Website www.bacitltd.com | 2 Polygon European Equity Opportunity | Polygon Global Partners | Hedge | Equities | 5.7% |
Investment Manager BACIT (UK)Limited | 3 Majedie UK Equity | Majedie Asset Management | Long Bias | Equities | 5.4% |
Administrator Northern Trust International | 4 Maga Smaller Companies UCITS | Otus Capital Management | Hedge | Equities | 5.0% |
Custodian Northern Trust (Guernsey) Ltd | 5 Tower Master Fund | Ten Five Capital Management | Hedge | Equities | 4.8% |
Registrar Capita Registrars (Guernsey) Limited | 6 Parity Value | Parity Asset Management Limited | Hedge | Macro | 4.7% |
Corporate Broker J.P. Morgan Cazenove | 7 SW Mitchell European | SW Mitchell Capital | Hedge | Equities | 4.6% |
8 Sinfonietta | Symphony Financial Partners | Hedge | Macro | 4.4% | |
9 Portland Hill | Portland Hill Capital | Hedge | Equities | 3.9% | |
10 Cumulus | City Financial Investment Co | Hedge | Commodity | 3.8% | |
Total | 48.7% | ||||
CHARITIES SUPPORTED BY BACIT |
The BACIT Foundation
The charitable objects of The BACIT Foundation relate primarily to the prevention, treatment, cure and ultimately eradication of cancer, but also cover diseases allied to cancer, and such other charitable objects and organisations as the Foundation may from time to time consider desirable.
The Institute Of Cancer Research
The Institute of Cancer Research, London, is one of the world's most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. Today, the ICR is ranked as the UK's leading academic research centre, and leads the world in isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment. The ICR employs leading scientists from over 50 countries around the world and since 2005 alone, 16 drug development candidates have been discovered based on ICR research, 6 of which have progressed into phase 1 clinical trials. The ICR has charitable status and relies on support from partner organisations, charities and donors to fund its research and innovation.
All Charities
Alzheimer's Research UK JDRF (The Juvenile Diabetes Research Foundation)
The Alzheimer's Society The Louis Dundas Centre For Children's Palliative Care
Beating Bowel Cancer Maggie's
Butterfly Thyroid Cancer Trust Marie Curie Cancer Care
Child Bereavement UK NSPCC
Cure Leukaemia The Rwanda Hope Foundation
Downside Up Scope
The Egmont Trust Skiing With Heroes
The Institute Of Cancer Research SSAFA Forces Help
The James Wentworth-Stanley Memorial Fund Women For Women International
BACIT (UK) Limited, 2nd Floor, 10 Aldermanbury, London EC2V 7RF Telephone: +44 20 3603 0453 Email: IR@bacit.co BACIT (UK) Limited, registered number 9066820, is authorised and regulated by the Financial Conduct Authority.BACIT Limited | |||||||
ASSET ALLOCATION (% OF NAV) | FUND STRATEGY ALLOCATION (% OF NAV) | ||||||
Cash Commodi Private Equity 3% 6% 5% Macro 12% Infrastructure 2% Fixed Income 3% Equity Long Bias 21% DENOMINATION OF INVESTMENTS (% OF NAV) | ty Credit 13% Equity Hedge 35% | Cash 3% Long Bias 34% Infrastructure 2% STRATEGY GEOGRAPHICAL FOCUS (% OF NAV) | Hedge 61% | ||||
US$ Partially Hedged into GBP, € Hedged into GBP, SEK Unhedged Cash 3% EUR (hedged) Emerging9% USD (hedged) 14% Asia-Pacific 14% 26% US 5% UK 8% Europe 41% GBP 34% Global 10% USD 25% SEK Europe & US 1% 10% NAV PERFORMANCE ANALYSIS ALLOCATION LIMITS | |||||||
Inception | 26 October 2012 | Current | Limit | % of | |||
NAV (£m) | £470.4 | Limit | |||||
1 Month Return | 0.08% | Asset Class | Equity Hedge | 35% | 80% | 43% | |
3 Month Return | -2.52% | Manager | Polygon Global Partners | 11% | 30% | 38% | |
YTD Return | -2.52% | Fund | Polar Capital Japan Alpha | 6% | 20% | 32% | |
Last 12 Months Return | -0.51% | ||||||
NAV Total Return Since Inception | 29.54% | INDEX ANALYSIS OF NAV PERFORMANCE | |||||
Annualised Return Since Inception | 7.87% | ||||||
Annualised Volatility Since Inception | 5.88% | Monthly comparative MSCI World | FT All-Share | HFRIFOFS | |||
Sharpe Ratio | 1.3 | (TR, $) | (TR, £) | Index | |||
Best Month | 4.12% | Alpha | 6% | 5% | 6% | ||
Worst Month | -2.56% | Beta | 0.21 | 0.35 | 0.72 | ||
% Positive Months | 63% | Correlation | 0.42 | 0.63 | 0.61 | ||
Largest Drawdown | -4.59% | Outperformance in Down Markets* | 93% | 94% | 71% | ||
*This measures the percentage of months when the benchmark falls, that BACIT outperforms it. | |||||||
DATA SOURCES: | |||||||
Data has been sourced from Bloomberg, Northern Trust, the Company's administrator, and the underlying funds. | |||||||
IMPORTANT INFORMATION AND LEGAL DISCLAIMER | |||||||
This fact sheet contains information regarding BACIT Limited's (the "Company's") performance and outlook. The information contained in the fact sheet is unaudited, and the reported NAVs of the underlying funds may have been subject to deductions in respect of management and performance fees which will not apply to the Company's investment. This fact sheet is provided for information purposes only and does not constitute an invitation or offer to subscribe for or purchase shares in the Company. The material provided is not intended to provide a sufficient basis on which to make an investment decision. Past performance is no guarantee of future returns and estimated results, performance or achievements may materially differ from actual results. All investments are subject to risk. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decisions. Information and opinions presented in the material contained on these pages relating to the Company and its investments have been obtained or derived from sources believed by the Company to be reliable, but the Company makes no representation as to their accuracy or completeness. Except as required by applicable law, the Company expressly disclaims any obligations to update or revise such estimates to reflect any change in expectations, new information, subsequent events or otherwise. |
Prepared by Mainspring Fund Services Limited E: bacit@mainspringfs.com W: mainspringfs.com
Registered charity numbers 216401 and SC037717
BACIT Limited issued this content on 28 April 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 28 April 2016 21:56:53 UTC
Original Document: http://www.bacitltd.com/wp-content/plugins/download-monitor/download.php?id=163